

**BEFORE THE  
BOARD OF PHARMACY  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA**

**In the Matter of the Accusation Against:**

**LIMA'S PROFESSIONAL PHARMACY INC., dba  
LIMA'S PROFESSIONAL PHARMACY;  
ROBERT LIMA, CEO and 50% SHAREHOLDER;  
RAMONA LIMA, SECRETARY and 50% SHAREHOLDER,  
Pharmacy Permit No. PHY 43124 and  
Sterile Compounding License No. LSC 100544;**

**and**

**RAMONA LIMA,  
Pharmacist License No. RPH 46446,**

**Respondents.**

**Agency Case No. 7269**

**OAH Case No. 2023080108**

## DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on June 5, 2024.

It is so ORDERED on May 6, 2024.

BOARD OF PHARMACY  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA

By

A handwritten signature in black ink, appearing to read "Seung W. Oh". The signature is written in a cursive, flowing style.

Seung W. Oh, Pharm.D.  
Board President

1 ROB BONTA  
Attorney General of California  
2 JOSHUA A. ROOM  
Supervising Deputy Attorney General  
3 CARTER OTT  
Deputy Attorney General  
4 State Bar No. 221660  
455 Golden Gate Avenue, Suite 11000  
5 San Francisco, CA 94102-7004  
Telephone: (415) 510-3485  
6 Facsimile: (415) 703-5480  
E-mail: Carter.Ott@doj.ca.gov  
7 *Attorneys for Complainant*

8  
9 **BEFORE THE**  
**BOARD OF PHARMACY**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**

12  
13 In the Matter of the Accusation Against:

14 **LIMA'S PROFESSIONAL PHARMACY**  
15 **INC., dba LIMA'S PROFESSIONAL**  
16 **PHARMACY; ROBERT LIMA, CEO and**  
17 **50% Shareholder; and RAMONA LIMA,**  
**Secretary and 50% Shareholder**  
2097 Harrison Avenue  
Eureka, CA 95501

18 **Pharmacy Permit No. PHY 43124**

19 **Sterile Compounding License No. LSC**  
**100544**

20 **RAMONA LIMA**  
21 2097 Harrison Avenue  
Eureka, CA 95501

22 **Pharmacist License No. RPH 46446**

23 Respondents.  
24

Case No. 7269

OAH Case No. 2023080108

**STIPULATED SETTLEMENT AND**  
**DISCIPLINARY ORDER**

1 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
2 entitled proceedings that the following matters are true:

3 **PARTIES**

4 1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy  
5 (Board). She brought this action solely in her official capacity and is represented in this matter by  
6 Rob Bonta, Attorney General of the State of California, by Carter Ott, Deputy Attorney General.

7 2. Respondents are represented in this proceeding by attorney Tony J. Park, Pharm.D.,  
8 J.D., whose address is: California Pharmacy Lawyers, Law Offices of Tony J. Park, Inc., 9090  
9 Irvine Center Drive, Irvine, CA 92618, telephone (949) 336-7854.

10 3. On or about December 16, 1997, the Board issued Pharmacy Permit Number PHY  
11 43124 to partners, Robert Brede Lima and Ramona Lima, 50% shareholders, to do business as  
12 Lima's Professional Pharmacy. On or about September 27, 2007, the Board authorized a  
13 tradestyle change to Permit Number PHY 43124, allowing Lima's Professional Pharmacy Inc., to  
14 do business as Lima's Professional Pharmacy (Respondent Lima's Pharmacy). The Pharmacy  
15 Permit is in full force and effect, and will expire on December 1, 2024, unless renewed.

16 4. On or about June 21, 2014, the Board issued Sterile Compounding License Number  
17 LSC 100544 to Respondent Lima's Pharmacy. The Sterile Compounding License is in full force  
18 and effect, and will expire on December 1, 2024, unless renewed.

19 5. On or about August 17, 1993, the Board issued Pharmacist License Number RPH  
20 46446 to Ramona Lima (Respondent Lima). The Pharmacist License is in full force and effect,  
21 and will expire on February 28, 2025, unless renewed. At all times relevant, Respondent Lima is  
22 and has been Secretary, 50% owner, and Pharmacist-in-Charge of Respondent Lima's Pharmacy.

23 6. At all times relevant, Robert Lima is and has been the Chief Executive Officer and  
24 50% owner of Respondent Lima's Pharmacy.

25 **JURISDICTION**

26 7. Accusation No. 7269 was filed before the Board, and is currently pending against  
27 Respondents. The Accusation and all other statutorily required documents were properly served

28 ///

1 on Respondents on March 16, 2023. Respondents timely filed their Notice of Defense contesting  
2 the Accusation.

3 8. A copy of Accusation No. 7269 is attached as Exhibit A and incorporated herein by  
4 reference.

5 **ADVISEMENT AND WAIVERS**

6 9. Respondents have carefully read, fully discussed with counsel, and understand the  
7 charges and allegations in Accusation No. 7269. Respondents have also carefully read, fully  
8 discussed with counsel, and understand the effects of this Stipulated Settlement and Disciplinary  
9 Order.

10 10. Respondents are fully aware of their legal rights in this matter, including the right to a  
11 hearing on the charges and allegations in the Accusation; the right to confront and cross-examine  
12 the witnesses against them; the right to present evidence and to testify on their own behalf; the  
13 right to the issuance of subpoenas to compel the attendance of witnesses and the production of  
14 documents; the right to reconsideration and court review of an adverse decision; and all other  
15 rights accorded by the California Administrative Procedure Act and other applicable laws.

16 11. Respondents voluntarily, knowingly, and intelligently waives and gives up each and  
17 every right set forth above.

18 **CULPABILITY**

19 12. Respondents admit the truth of each and every charge and allegation in Accusation  
20 No. 7269.

21 13. Respondents agree that their Pharmacy Permit, Sterile Compounding License, and  
22 Pharmacist License are subject to discipline and they agree to be bound by the Board's  
23 probationary terms as set forth in the Disciplinary Order below.

24 **CONTINGENCY**

25 14. This stipulation shall be subject to approval by the Board of Pharmacy. Respondents  
26 understand and agree that counsel for Complainant and the staff of the Board of Pharmacy may  
27 communicate directly with the Board regarding this stipulation and settlement, without notice to  
28 or participation by Respondents or their counsel. By signing the stipulation, Respondents

1 understand and agree that they may not withdraw their agreement or seek to rescind the  
2 stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this  
3 stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of  
4 no force or effect, except for this paragraph, it shall be inadmissible in any legal action between  
5 the parties, and the Board shall not be disqualified from further action by having considered this  
6 matter.

7 15. The parties understand and agree that Portable Document Format (PDF) and facsimile  
8 copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile  
9 signatures thereto, shall have the same force and effect as the originals.

10 16. This Stipulated Settlement and Disciplinary Order is intended by the parties to be an  
11 integrated writing representing the complete, final, and exclusive embodiment of their agreement.  
12 It supersedes any and all prior or contemporaneous agreements, understandings, discussions,  
13 negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary  
14 Order may not be altered, amended, modified, supplemented, or otherwise changed except by a  
15 writing executed by an authorized representative of each of the parties.

16 17. In consideration of the foregoing admissions and stipulations, the parties agree that  
17 the Board may, without further notice or formal proceeding, issue and enter the following  
18 Disciplinary Orders:

19 **DISCIPLINARY ORDER – LIMA’S PROFESSIONAL PHARMACY INC.**

20 IT IS HEREBY ORDERED that Pharmacy Permit No. PHY 43124 and Sterile  
21 Compounding License No. LSC 100544, issued to Lima’s Professional Pharmacy Inc., doing  
22 business as Lima’s Professional Pharmacy are revoked; however, the revocations are stayed and  
23 Pharmacy Permit No. PHY 43124 and Sterile Compounding License No. LSC 100544 are placed  
24 on probation for three (3) years on the following terms and conditions:

25 **1. Definition: Respondent Lima’s Pharmacy**

26 For the purposes of these terms and conditions, “Respondent Lima’s Pharmacy” shall refer  
27 to Respondent Lima’s Professional Pharmacy, doing business as Lima’s Professional Pharmacy.  
28 All terms and conditions stated herein shall bind and be applicable to the licensed premises and to

1 all owners, managers, officers, administrators, members, directors, trustees, associates, or partners  
2 thereof. For purposes of compliance with any term or condition, any report, submission, filing,  
3 payment, or appearance required to be made by Respondent Lima's Pharmacy to or before the  
4 Board or its designee shall be made by an owner or executive officer with authority to act on  
5 behalf of and legally bind the licensed entity.

6 **2. Obey All Laws**

7 Respondent Lima's Pharmacy shall obey all state and federal laws and regulations.

8 Respondent Lima's Pharmacy shall report any of the following occurrences to the Board, in  
9 writing, within seventy-two (72) hours of such occurrence:

- 10 • an arrest or issuance of a criminal complaint for violation of any provision of the  
11 Pharmacy Law, state and federal food and drug laws, or state and federal controlled  
12 substances laws
- 13 • a plea of guilty, or nolo contendere, no contest, or similar, in any state or federal  
14 criminal proceeding to any criminal complaint, information or indictment
- 15 • a conviction of any crime
- 16 • the filing of a disciplinary pleading, issuance of a citation, or initiation of another  
17 administrative action filed by any state or federal agency which involves  
18 Respondent Lima's Pharmacy license or which is related to the practice of  
19 pharmacy or the manufacturing, obtaining, handling, distributing, billing, or  
20 charging for any drug, device or controlled substance.

21 Failure to timely report such occurrence shall be considered a violation of probation.

22 **3. Report to the Board**

23 Respondent Lima's Pharmacy shall report to the Board quarterly, on a schedule as directed  
24 by the Board or its designee. The report shall be made either in person or in writing, as directed.  
25 Among other requirements, Respondent Lima's Pharmacy shall state in each report under penalty  
26 of perjury whether there has been compliance with all the terms and conditions of probation.

27 Failure to submit timely reports in a form as directed shall be considered a violation of  
28 probation. Any period(s) of delinquency in submission of reports as directed may be added to the

1 total period of probation. Moreover, if the final probation report is not made as directed,  
2 probation shall be automatically extended until such time as the final report is made and accepted  
3 by the Board.

4 **4. Interview with the Board**

5 Upon receipt of reasonable prior notice, Respondent Lima's Pharmacy shall appear in  
6 person for interviews with the Board or its designee, at such intervals and locations as are  
7 determined by the Board or its designee. Failure to appear for any scheduled interview without  
8 prior notification to Board staff, or failure to appear for two (2) or more scheduled interviews  
9 with the Board or its designee during the period of probation, shall be considered a violation of  
10 probation.

11 **5. Cooperate with Board Staff**

12 Respondent Lima's Pharmacy shall timely cooperate with the Board's inspection program  
13 and with the Board's monitoring and investigation of Respondent Lima's Pharmacy compliance  
14 with the terms and conditions of its probation, including but not limited to: timely responses to  
15 requests for information by Board staff; timely compliance with directives from Board staff  
16 regarding requirements of any term or condition of probation; and timely completion of  
17 documentation pertaining to a term or condition of probation. Failure to timely cooperate shall be  
18 considered a violation of probation.

19 **6. Reimbursement of Board Costs**

20 Respondent Lima's Pharmacy and Respondent Lima are jointly and severally responsible  
21 for reimbursement of the Board's costs of investigation and prosecution in the amount of  
22 \$10,000.00, accordingly, as a condition precedent to successful completion of probation,  
23 Respondent Lima's Pharmacy and/or Respondent Lima shall pay to the Board its costs of  
24 investigation and prosecution in the amount of \$10,000.00.

25 Respondent Lima's Pharmacy and/or Respondent Lima shall be permitted to pay these costs  
26 in a payment plan approved by the Board or its designee, so long as full payment is completed no  
27 later than one (1) year prior to the end date of probation.

28 ///



1           **7. Probation Monitoring Costs**

2           Respondent Lima's Pharmacy shall pay any costs associated with probation monitoring as  
3 determined by the Board each and every year of probation. Such costs shall be payable to the  
4 Board on a schedule as directed by the Board or its designee. Failure to pay such costs by the  
5 deadline(s) as directed shall be considered a violation of probation.

6           **8. Status of License**

7           Respondent Lima's Pharmacy shall, at all times while on probation, maintain an active,  
8 current Pharmacy Permit and Sterile Compounding License with the Board, including any period  
9 during which suspension or probation is tolled. Failure to maintain an active, current Pharmacy  
10 Permit and Sterile Compounding License shall be considered a violation of probation.

11           If Respondent Lima's Pharmacy's Pharmacy Permit or Sterile Compounding License expire  
12 or are cancelled by operation of law or otherwise at any time during the period of probation,  
13 including any extensions thereof due to tolling or otherwise, upon renewal or reapplication  
14 Respondent Lima's Pharmacy's Pharmacy Permit or Sterile Compounding License shall be  
15 subject to all terms and conditions of this probation not previously satisfied.

16           **9. License Surrender While on Probation/Suspension**

17           Following the effective date of this decision, should Respondent Lima's Pharmacy cease  
18 practice due to retirement or health, or be otherwise unable to satisfy the terms and conditions of  
19 probation, Respondent Lima's Pharmacy may relinquish its Pharmacy Permit, including any  
20 indicia of licensure issued by the Board, along with a request to surrender the license. The Board  
21 or its designee shall have the discretion whether to accept the surrender or take any other action it  
22 deems appropriate and reasonable. Upon formal acceptance of the surrender of the licenses,  
23 Respondent Lima's Pharmacy will no longer be subject to the terms and conditions of probation.  
24 This surrender constitutes a record of discipline and shall become a part of the Respondent  
25 Lima's Pharmacy's license history with the Board.

26           Upon acceptance of the surrender, Respondent Lima's Pharmacy shall relinquish its pocket  
27 and/or wall license, including any indicia of licensure not previously provided to the Board within  
28 ten (10) days of notification by the Board that the surrender is accepted if not already provided.

Respondent Lima's Pharmacy may not reapply for any license from the Board for three (3) years from the effective date of the surrender. Respondent Lima's Pharmacy shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the Board, including any outstanding costs.

#### **10. Sale or Discontinuance of Business**

During the period of probation, should Respondent Lima's Pharmacy sell, trade or transfer all or part of the ownership of the licensed entity, discontinue doing business under the license issued to Respondent Lima's Pharmacy, or should practice at that location be assumed by another full or partial owner, person, firm, business, or entity, under the same or a different premises license number, the Board or its designee shall have the sole discretion to determine whether to exercise continuing jurisdiction over the licensed location, under the current or new premises license number, and/or carry the remaining period of probation forward to be applicable to the current or new premises license number(s) of the new owner.

#### **11. Notice to Employees**

Respondent Lima's Pharmacy shall, upon or before the effective date of this decision, ensure that all employees involved in permit operations are made aware of all the terms and conditions of probation, either by posting a notice of the terms and conditions, circulating such notice, or both. If the notice required by this provision is posted, it shall be posted in a prominent place and shall remain posted throughout the probation period. Respondent Lima's Pharmacy shall ensure that any employees hired or used after the effective date of this decision are made aware of the terms and conditions of probation by posting a notice, circulating a notice, or both. Additionally, Respondent Lima's Pharmacy shall submit written notification to the Board, within fifteen (15) days of the effective date of this decision, that this term has been satisfied. Failure to timely provide such notification to employees, or to timely submit such notification to the Board shall be considered a violation of probation.

"Employees" as used in this provision includes all full-time, part-time, volunteer, temporary and relief employees and independent contractors employed or hired at any time during probation.

1           **12. Owners and Officers: Knowledge of the Law**

2           Respondent Lima's Pharmacy shall provide, within thirty (30) days after the effective date  
3 of this decision, signed and dated statements from its owners, including any owner or holder of  
4 ten percent (10%) or more of the interest in Respondent Lima's Pharmacy or Respondent Lima's  
5 Pharmacy's stock, and all of its officers, stating under penalty of perjury that said individuals  
6 have read and are familiar with state and federal laws and regulations governing the practice of  
7 pharmacy. The failure to timely provide said statements under penalty of perjury shall be  
8 considered a violation of probation.

9           **13. Premises Open for Business**

10          Respondent Lima's Pharmacy shall remain open and engaged in its ordinary business as a  
11 pharmacy in California for a minimum of 120 hours per calendar month. Any month during  
12 which this minimum is not met shall toll the period of probation, i.e., the period of probation shall  
13 be extended by one month for each month during with this minimum is not met. During any such  
14 period of tolling of probation, Respondent Lima's Pharmacy must nonetheless comply with all  
15 terms and conditions of probation, unless Respondent Lima's Pharmacy is informed otherwise in  
16 writing by the Board or its designee. If Respondent Lima's Pharmacy is not open and engaged in  
17 its ordinary business as a pharmacy for a minimum of 120 hours in any calendar month, for any  
18 reason (including vacation), Respondent Lima's Pharmacy shall notify the Board in writing  
19 within ten (10) days of the conclusion of that calendar month. This notification shall include at  
20 minimum all of the following: the date(s) and hours Respondent Lima's Pharmacy was open; the  
21 reason(s) for the interruption or why business was not conducted; and the anticipated date(s) on  
22 which Respondent Lima's Pharmacy will resume business as required. Respondent Lima's  
23 Pharmacy shall further notify the Board in writing with ten (10) days following the next calendar  
24 month during which Respondent Lima's Pharmacy is open and engaged in its ordinary business  
25 as a pharmacy in California for a minimum of hours. Any failure to timely provide such  
26 notification(s) shall be considered a violation of probation.

27       ///

28       ///

1           **14. Posted Notice of Probation**

2           Respondent Lima's Pharmacy shall prominently post a probation notice provided by the  
3 Board or its designee in a place conspicuous to and readable by the public within two (2) days of  
4 receipt thereof from the Board or its designee. Failure to timely post such notice, or to maintain  
5 the posting during the entire period of probation, shall be considered a violation of probation.

6           Respondent Lima's Pharmacy shall not, directly or indirectly, engage in any conduct or  
7 make any statement which is intended to mislead or is likely to have the effect of misleading any  
8 patient, customer, member of the public, or other person(s) as to the nature of and reason for the  
9 probation of the licensed entity.

10           **15. Violation of Probation**

11           If Respondent Lima's Pharmacy has not complied with any term or condition of probation,  
12 the Board shall have continuing jurisdiction over Respondent Lima's Pharmacy, and the Board  
13 shall provide notice to Respondent Lima's Pharmacy that probation shall automatically be  
14 extended, until all terms and conditions have been satisfied or the Board has taken other action as  
15 deemed appropriate to treat the failure to comply as a violation of probation, to terminate  
16 probation, and to impose the penalty that was stayed. The Board or its designee may post a notice  
17 of the extended probation period on its website.

18           If Respondent Lima's Pharmacy violates probation in any respect, the Board, after giving  
19 Respondent Lima's Pharmacy notice and an opportunity to be heard, may revoke probation and  
20 carry out the disciplinary order that was stayed. If a petition to revoke probation or an accusation  
21 is filed against Respondent Lima's Pharmacy during probation, or the preparation of an  
22 accusation or petition to revoke probation is requested from the Office of the Attorney General,  
23 the Board shall have continuing jurisdiction and the period of probation shall be automatically  
24 extended until the petition to revoke probation or accusation is heard and decided.

25           **16. Completion of Probation**

26           Upon written notice by the Board or its designee indicating successful completion of  
27 probation, Respondent Lima's Pharmacy's Pharmacy Permit and Sterile Compounding License  
28 will be fully restored.

1           **17. Remedial Education**

2           Within thirty (30) days of the effective date of this decision, Respondent Lima's Pharmacy  
3 shall submit to the Board or its designee, for prior approval, an appropriate program of remedial  
4 education, to be completed by Respondent Lima's Pharmacy's staff responsible for compounding  
5 sterile drug preparations, related to compounding sterile drug preparations (USP 797). The  
6 program of remedial education shall consist of at least 6 hours (fifty-percent of which must be  
7 completed in-person) per staff member, which shall be completed within six (6) months of the  
8 effective date of this decision at Respondent Lima's Pharmacy own expense.

9           This remedial education shall be completed by staff of Respondent Lima's Pharmacy  
10 responsible for compounding sterile drug preparations other than Respondent Ramona Lima. All  
11 remedial education shall be in addition to, and shall not be credited toward, continuing education  
12 (CE) courses used for license renewal purposes for pharmacists.

13           Failure to timely submit for approval or complete the approved remedial education shall be  
14 considered a violation of probation. The period of probation will be automatically extended until  
15 such remedial education is successfully completed and written proof, in a form acceptable to the  
16 Board, is provided to the Board or its designee.

17           Following the completion of the approved remedial education, the Board or its designee  
18 may require Respondent Lima's Pharmacy staff responsible for compounding sterile drug  
19 preparations, at Respondent Lima's Pharmacy's own expense, to take an approved examination to  
20 test his, her, and/or their knowledge of the course(s). If a sterile-drug-compounding staff member  
21 does not achieve a passing score on the examination, that course shall not count towards  
22 satisfaction of this term. That staff member shall take another course approved by the Board in  
23 the same subject area.

24           **18. No Additional Ownership or Management of Licensed Premises**

25           Respondent Lima's Pharmacy shall not acquire any additional ownership, legal or  
26 beneficial interest in, nor serve as a manager, administrator, member, officer, director, associate,  
27 partner or any business, firm, partnership, or corporation currently or hereinafter licensed by the

28       ///

Board except as approved by the Board or its designee. Violations of this restriction shall be considered a violation of probation.

**DISCIPLINARY ORDER – RESPONDENT RAMONA LIMA**

IT IS HEREBY ORDERED that Pharmacist License Number RPH 46446, issued to Respondent Ramona Lima (Respondent Lima), is revoked. However, the revocation is stayed and Respondent Lima is placed on probation for three (3) years on the following terms and conditions:

**1. Obey All Laws**

Respondent Lima shall obey all state and federal laws and regulations.

Respondent Lima shall report any of the following occurrences to the Board, in writing, within seventy-two (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
- a plea of guilty, or nolo contendere, no contest, or similar, in any state or federal criminal proceeding to any criminal complaint, information or indictment
- a conviction of any crime
- the filing of a disciplinary pleading, issuance of a citation, or initiation of another administrative action filed by any state or federal agency which involves Respondent Lima's license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling, distributing, billing, or charging for any drug, device or controlled substance.

Failure to timely report such occurrence shall be considered a violation of probation.

**2. Report to the Board**

Respondent Lima shall report to the Board quarterly, on a schedule as directed by the Board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, Respondent Lima shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation.

1 Failure to submit timely reports in a form as directed shall be considered a violation of  
2 probation. Any period(s) of delinquency in submission of reports as directed may be added to the  
3 total period of probation. Moreover, if the final probation report is not made as directed,  
4 probation shall be automatically extended until such time as the final report is made and accepted  
5 by the Board.

### 6 **3. Interview with the Board**

7 Upon receipt of reasonable prior notice, Respondent Lima shall appear in person for  
8 interviews with the Board or its designee, at such intervals and locations as are determined by the  
9 Board or its designee. Failure to appear for any scheduled interview without prior notification to  
10 Board staff, or failure to appear for two (2) or more scheduled interviews with the Board or its  
11 designee during the period of probation, shall be considered a violation of probation.

### 12 **4. Cooperate with Board Staff**

13 Respondent Lima shall timely cooperate with the Board's inspection program and with the  
14 Board's monitoring and investigation of Respondent Lima's compliance with the terms and  
15 conditions of her probation, including but not limited to: timely responses to requests for  
16 information by Board staff; timely compliance with directives from Board staff regarding  
17 requirements of any term or condition of probation; and timely completion of documentation  
18 pertaining to a term or condition of probation. Failure to timely cooperate shall be considered a  
19 violation of probation.

### 20 **5. Continuing Education**

21 Respondent Lima shall provide evidence of efforts to maintain skill and knowledge as a  
22 pharmacist as directed by the Board or its designee.

### 23 **6. Reporting of Employment and Notice to Employers**

24 During the period of probation, Respondent Lima shall notify all present and prospective  
25 employers of the decision in case number 7269 and the terms, conditions and restrictions imposed  
26 on Respondent Lima by the decision, as follows:

27 Within thirty (30) days of the effective date of this decision, and within ten (10) days of  
28 undertaking any new employment, Respondent Lima shall report to the Board in writing the



1 name, physical address, and mailing address of each of her employer(s), and the name(s) and  
2 telephone number(s) of all of her direct supervisor(s), as well as any pharmacist(s)-in-charge,  
3 designated representative(s)-in-charge, responsible manager, or other compliance supervisor(s)  
4 and the work schedule, if known. Respondent Lima shall also include the reason(s) for leaving  
5 the prior employment. Respondent Lima shall sign and return to the Board a written consent  
6 authorizing the Board or its designee to communicate with all of Respondent Lima's employer(s)  
7 and supervisor(s), and authorizing those employer(s) or supervisor(s) to communicate with the  
8 Board or its designee, concerning Respondent Lima's work status, performance, and monitoring.  
9 Failure to comply with the requirements or deadlines of this condition shall be considered a  
10 violation of probation.

11 Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of  
12 Respondent Lima's undertaking any new employment, Respondent Lima shall cause (a) her direct  
13 supervisor, (b) her pharmacist-in-charge, designated representative-in-charge, responsible  
14 manager, or other compliance supervisor, and (c) the owner or owner representative of her  
15 employer, to report to the Board in writing acknowledging that the listed individual(s) has/have  
16 read the decision in case number 7269, and terms and conditions imposed thereby. If one person  
17 serves in more than one role described in (a), (b), or (c), the acknowledgment shall so state. It  
18 shall be the Respondent Lima's responsibility to ensure that these acknowledgment(s) are timely  
19 submitted to the Board. In the event of a change in the person(s) serving the role(s) described in  
20 (a), (b), or (c) during the term of probation, Respondent Lima shall cause the person(s) taking  
21 over the role(s) to report to the Board in writing within fifteen (15) days of the change  
22 acknowledging that he or she has read the decision in case number 7269, and the terms and  
23 conditions imposed thereby.

24 If Respondent Lima works for or is employed by or through an employment service,  
25 Respondent Lima must notify the person(s) described in (a), (b), and (c) above at every entity  
26 licensed by the Board of the decision in case number 7269, and the terms and conditions imposed  
27 thereby in advance of Respondent Lima commencing work at such licensed entity. A record of  
28 this notification must be provided to the Board upon request.



1 Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen  
2 (15) days of Respondent Lima undertaking any new employment by or through an employment  
3 service, Respondent Lima shall cause the person(s) described in (a), (b), and (c) above at the  
4 employment service to report to the Board in writing acknowledging that he or she has read the  
5 decision in case number, and the terms and conditions imposed thereby. It shall be Respondent  
6 Lima's responsibility to ensure that these acknowledgment(s) are timely submitted to the Board.

7 Failure to timely notify present or prospective employer(s) or failure to cause the identified  
8 person(s) with that/those employer(s) to submit timely written acknowledgments to the Board  
9 shall be considered a violation of probation.

10 "Employment" within the meaning of this provision includes any full-time, part-time,  
11 temporary, relief, or employment/management service position as a pharmacist, or any position  
12 for which a pharmacist is a requirement or criterion for employment, whether Respondent Lima is  
13 an employee, independent contractor or volunteer.

14 **7. Notification of Change(s) in Name, Address(es), or Phone Number(s)**

15 Respondent Lima shall further notify the Board in writing within ten (10) days of any  
16 change in name, residence address, mailing address, e-mail address or phone number.

17 Failure to timely notify the Board of any change in employer, name, address, or phone  
18 number shall be considered a violation of probation.

19 **8. Restrictions on Supervision and Oversight of Licensed Facilities**

20 During the period of probation, Respondent Lima shall not supervise any intern pharmacist  
21 or serve as a consultant to any entity licensed by the Board. Respondent Lima may be a  
22 pharmacist-in-charge, designated representative-in-charge, responsible manager or other  
23 compliance supervisor of any single entity licensed by the Board, but only if Respondent Lima or  
24 that entity retains, at her/its expense, an independent consultant who shall be responsible for  
25 reviewing the operations of the entity on a quarterly basis for compliance by Respondent Lima  
26 and the entity with state and federal laws and regulations governing the practice of the entity, and  
27 compliance by Respondent Lima with the obligations of her supervisory position. The quarterly  
28 review may be conducted remotely, via videoconference; however, at least one review per

1 calendar year shall be conducted in-person. Respondent Lima may serve in such a position at  
2 only one entity licensed by the Board, only upon approval by the Board or its designee. Any such  
3 approval shall be site specific. The consultant shall be a pharmacist licensed by and not on  
4 probation with the Board, who has been approved by the Board or its designee to serve in this  
5 position. Respondent Lima shall submit the name of the proposed consultant to the Board or its  
6 designee for approval within thirty (30) days of the effective date of the decision or prior to  
7 assumption of duties allowed in this term. Assumption of any unauthorized supervision  
8 responsibilities shall be considered a violation of probation. In addition, failure to timely seek  
9 approval for, timely retain, or ensure timely reporting by the consultant shall be considered a  
10 violation of probation.

#### 11 **9. Reimbursement of Board Costs**

12 Respondent Lima and Respondent Lima's Pharmacy are jointly and severally responsible  
13 for reimbursement of the Board's costs of investigation and prosecution in the amount of  
14 \$10,000.00. Accordingly, as a condition precedent to successful completion of probation,  
15 Respondent Lima and/or Respondent Lima's Pharmacy shall pay to the Board its costs of  
16 investigation and prosecution in the amount of \$10,000.00.

17 Respondent Lima and/or Respondent Lima's Pharmacy shall be permitted to pay these costs  
18 in a payment plan approved by the Board or its designee, so long as full payment is completed no  
19 later than one (1) year prior to the end date of probation.

#### 20 **10. Probation Monitoring Costs**

21 Respondent Lima shall pay any costs associated with probation monitoring as determined  
22 by the Board each and every year of probation. Such costs shall be payable to the Board on a  
23 schedule as directed by the Board or its designee. Failure to pay such costs by the deadline(s) as  
24 directed shall be considered a violation of probation.

#### 25 **11. Status of License**

26 Respondent Lima shall, at all times while on probation, maintain an active, current  
27 Pharmacist License with the Board, including any period during which suspension or probation is

28 ///

1 tolled. Failure to maintain an active, current Pharmacist License shall be considered a violation  
2 of probation.

3 If Respondent Lima's Pharmacist License expires or is cancelled by operation of law or  
4 otherwise at any time during the period of probation, including any extensions thereof due to  
5 tolling or otherwise, upon renewal or reapplication Respondent Lima's license shall be subject to  
6 all terms and conditions of this probation not previously satisfied.

### 7 **12. License Surrender While on Probation/Suspension**

8 Following the effective date of this decision, should Respondent Lima cease practice due to  
9 retirement or health, or be otherwise unable to satisfy the terms and conditions of probation,  
10 Respondent Lima may relinquish her Pharmacist License, including any indicia of licensure  
11 issued by the Board, along with a request to surrender the license. The Board or its designee shall  
12 have the discretion whether to accept the surrender or take any other action it deems appropriate  
13 and reasonable. Upon formal acceptance of the surrender of the license, Respondent Lima will no  
14 longer be subject to the terms and conditions of probation. This surrender constitutes a record of  
15 discipline and shall become a part of the Respondent Lima's license history with the Board.

16 Upon acceptance of the surrender, Respondent Lima shall relinquish her pocket and/or wall  
17 license, including any indicia of licensure not previously provided to the Board within ten (10)  
18 days of notification by the Board that the surrender is accepted if not already provided.  
19 Respondent Lima may not reapply for any license from the Board for three (3) years from the  
20 effective date of the surrender. Respondent Lima shall meet all requirements applicable to the  
21 license sought as of the date the application for that license is submitted to the Board, including  
22 any outstanding costs.

### 23 **13. Practice Requirement – Extension of Probation**

24 Except during periods of suspension, Respondent Lima shall, at all times while on  
25 probation, be employed as a pharmacist in California for a minimum of 100 hours per calendar  
26 month. Any month during which this minimum is not met shall extend the period of probation by  
27 one month. During any such period of insufficient employment, Respondent Lima must

28 ///

1 nonetheless comply with all terms and conditions of probation, unless Respondent Lima receives  
2 a waiver in writing from the Board or its designee.

3 If Respondent Lima does not practice as a pharmacist in California for the minimum  
4 number of hours in any calendar month, for any reason (including vacation), Respondent Lima  
5 shall notify the Board in writing within ten (10) days of the conclusion of that calendar month.  
6 This notification shall include at least: the date(s), location(s), and hours of last practice; the  
7 reason(s) for the interruption or reduction in practice; and the anticipated date(s) on which  
8 Respondent Lima will resume practice at the required level. Respondent Lima shall further notify  
9 the Board in writing within ten (10) days following the next calendar month during which  
10 Respondent Lima practices as a pharmacist in California for the minimum of hours. Any failure  
11 to timely provide such notification(s) shall be considered a violation of probation.

12 It is a violation of probation for Respondent Lima's probation to be extended pursuant to  
13 the provisions of this condition for a total period, counting consecutive and non-consecutive  
14 months, exceeding thirty-six (36) months. The Board or its designee may post a notice of the  
15 extended probation period on its website.

#### 16 **14. Violation of Probation**

17 If Respondent Lima has not complied with any term or condition of probation, the Board  
18 shall have continuing jurisdiction over Respondent Lima, and the Board shall provide notice to  
19 Respondent Lima that probation shall automatically be extended, until all terms and conditions  
20 have been satisfied or the Board has taken other action as deemed appropriate to treat the failure  
21 to comply as a violation of probation, to terminate probation, and to impose the penalty that was  
22 stayed. The Board or its designee may post a notice of the extended probation period on its  
23 website.

24 If Respondent Lima violates probation in any respect, the Board, after giving Respondent  
25 Lima notice and an opportunity to be heard, may revoke probation and carry out the disciplinary  
26 order that was stayed. If a petition to revoke probation or an accusation is filed against  
27 Respondent Lima during probation, or the preparation of an accusation or petition to revoke  
28 probation is requested from the Office of the Attorney General, the Board shall have continuing

jurisdiction and the period of probation shall be automatically extended until the petition to revoke probation or accusation is heard and decided.

#### **15. Completion of Probation**

Upon written notice by the Board or its designee indicating successful completion of probation, Respondent Lima's Pharmacy License will be fully restored.

#### **16. Remedial Education**

Within thirty (30) days of the effective date of this decision, Respondent Lima shall submit to the Board or its designee, for prior approval, an appropriate program of remedial education related to compounding sterile drug preparations (USP 797). The program of remedial education shall consist of at least 10 hours (fifty-percent of which must be completed in-person), which shall be completed within two (2) years of the effective date of this decision at Respondent Lima's own expense. All remedial education shall be in addition to, and shall not be credited toward, continuing education (CE) courses used for license renewal purposes for pharmacists.

Failure to timely submit for approval or complete the approved remedial education shall be considered a violation of probation. The period of probation will be automatically extended until such remedial education is successfully completed and written proof, in a form acceptable to the Board, is provided to the Board or its designee.

Following the completion of each course, the Board or its designee may require Respondent Lima, at her own expense, to take an approved examination to test Respondent Lima's knowledge of the course. If Respondent Lima does not achieve a passing score on the examination, that course shall not count towards satisfaction of this term. Respondent Lima shall take another course approved by the Board in the same subject area.

#### **17. No Additional Ownership or Management of Licensed Premises**

Respondent Lima shall not acquire any new ownership, legal or beneficial interest nor serve as a manager, administrator, member, officer, director, trustee, associate, or partner of any additional business, firm, partnership, or corporation licensed by the board. If Respondent Lima currently owns or has any legal or beneficial interest in, or serves as a manager, administrator, member, officer, director, trustee, associate, or partner of any business, firm, partnership, or

1 corporation currently or hereinafter licensed by the Board, Respondent Lima may continue to  
2 serve in such capacity or hold that interest, but only to the extent of that position or interest as of  
3 the effective date of this decision. Violation of this restriction shall be considered a violation of  
4 probation.

5 **ACCEPTANCE**

6 I am authorized to enter into this agreement, and sign and bind this agreement, on behalf of  
7 Respondent Lima's Professional Pharmacy, Inc., doing business as Lima's Professional  
8 Pharmacy. I have carefully read the above Stipulated Settlement and Disciplinary Order and have  
9 fully discussed it with my attorney, Tony J. Park, Pharm.D., J.D. I understand the stipulation and  
10 the effect it will have on the current Pharmacy Permit and Sterile Compounding License, as well  
11 as on any subsequent outsourcing facility license that may be issued by the Board of Pharmacy. I  
12 enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and  
13 intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.

14  
15 DATED: \_\_\_\_\_

16 ROBERT LIMA  
17 Chief Executive Officer on behalf of  
18 *Lima's Professional Pharmacy, Inc., dba Lima's*  
19 *Professional Pharmacy*  
20 *Respondent*

21 **ACCEPTANCE**

22 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully  
23 discussed it with my attorney, Tony J. Park, Pharm.D., J.D. I understand the stipulation and the  
24 effect it will have on my Pharmacist License. I enter into this Stipulated Settlement and  
25 Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the  
26 Decision and Order of the Board of Pharmacy.

27 DATED: \_\_\_\_\_

28 RAMONA LIMA  
*Respondent*



1 corporation currently or hereinafter licensed by the Board, Respondent Lima may continue to  
2 serve in such capacity or hold that interest, but only to the extent of that position or interest as of  
3 the effective date of this decision. Violation of this restriction shall be considered a violation of  
4 probation.

5 **ACCEPTANCE**

6 I am authorized to enter into this agreement, and sign and bind this agreement, on behalf of  
7 Respondent Lima's Professional Pharmacy, Inc., doing business as Lima's Professional  
8 Pharmacy. I have carefully read the above Stipulated Settlement and Disciplinary Order and have  
9 fully discussed it with my attorney, Tony J. Park, Pharm.D., J.D. I understand the stipulation and  
10 the effect it will have on the current Pharmacy Permit and Sterile Compounding License, as well  
11 as on any subsequent outsourcing facility license that may be issued by the Board of Pharmacy. I  
12 enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and  
13 intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.

14  
15 DATED: 11-16-23

  
16 ROBERT LIMA

17 Chief Executive Officer on behalf of  
18 *Lima's Professional Pharmacy, Inc., dba Lima's*  
*Professional Pharmacy*  
*Respondent*

19 **ACCEPTANCE**

20 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully  
21 discussed it with my attorney, Tony J. Park, Pharm.D., J.D. I understand the stipulation and the  
22 effect it will have on my Pharmacist License. I enter into this Stipulated Settlement and  
23 Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the  
24 Decision and Order of the Board of Pharmacy.

25  
26 DATED: 11-16-23

  
27 RAMONA LIMA  
28 *Respondent*

1 I have read and fully discussed with Respondent Lima's Professional Pharmacy, Inc., doing  
2 business as Lima's Professional Pharmacy, and Respondent Ramona Lima, the terms and  
3 conditions and other matters contained in this Stipulated Settlement and Disciplinary Order. I  
4 approve its form and content.

5 DATED: \_\_\_\_\_  
6 TONY J. PARK, Pharm.D., J.D.  
7 CALIFORNIA PHARMACY LAWYERS  
8 *Attorney for Respondents*

9 **ENDORSEMENT**

10 The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully  
11 submitted for consideration by the Board of Pharmacy.

12 DATED: \_\_\_\_\_ Respectfully submitted,  
13  
14 ROB BONTA  
15 Attorney General of California  
16 JOSHUA A. ROOM  
17 Supervising Deputy Attorney General


18 CARTER OTT  
19 Deputy Attorney General  
20 *Attorneys for Complainant*

21  
22 SF2022400514 / 43953335.docx  
23  
24  
25  
26  
27  
28



1 I have read and fully discussed with Respondent Lima's Professional Pharmacy, Inc., doing  
2 business as Lima's Professional Pharmacy, and Respondent Ramona Lima, the terms and  
3 conditions and other matters contained in this Stipulated Settlement and Disciplinary Order. I  
4 approve its form and content.

5 DATED: 11/17/2023

  
6 TONY J. PARK, Pharm.D., J.D.  
7 CALIFORNIA PHARMACY LAWYERS  
8 *Attorney for Respondents*

9 **ENDORSEMENT**

10 The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully  
11 submitted for consideration by the Board of Pharmacy.

12 DATED: \_\_\_\_\_

13 Respectfully submitted,

14 **ROBBONTA**  
15 Attorney General of California  
16 **JOSHUA A. ROOM**  
17 Supervising Deputy Attorney General

18 **CARTER OTT**  
19 Deputy Attorney General  
20 *Attorneys for Complainant*

21  
22 SF2022400514 / 43953335.docx  
23  
24  
25  
26  
27  
28

1 I have read and fully discussed with Respondent Lima's Professional Pharmacy, Inc., doing  
2 business as Lima's Professional Pharmacy, and Respondent Ramona Lima, the terms and  
3 conditions and other matters contained in this Stipulated Settlement and Disciplinary Order. I  
4 approve its form and content.

5 DATED: \_\_\_\_\_

6 TONY J. PARK, Pharm.D., J.D.  
7 CALIFORNIA PHARMACY LAWYERS  
8 *Attorney for Respondents*

9 **ENDORSEMENT**

10 The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully  
11 submitted for consideration by the Board of Pharmacy.

12 DATED: November 17, 2023

13 Respectfully submitted,

14 ROB BONTA  
15 Attorney General of California  
16 JOSHUA A. ROOM  
17 Supervising Deputy Attorney General

18 

19 CARTER OTT  
20 Deputy Attorney General  
21 *Attorneys for Complainant*

22 SF2022400514 / 43953335.docx  
23  
24  
25  
26  
27  
28

**Exhibit A**

**Accusation No. 7269**

1 ROB BONTA  
Attorney General of California  
2 JOSHUA A. ROOM  
Supervising Deputy Attorney General  
3 CARTER OTT  
Deputy Attorney General  
4 State Bar No. 221660  
455 Golden Gate Avenue, Suite 11000  
5 San Francisco, CA 94102-7004  
Telephone: (415) 510-3485  
6 Facsimile: (415) 703-5480  
E-mail: Carter.Ott@doj.ca.gov  
7 *Attorneys for Complainant*

8  
9 **BEFORE THE**  
**BOARD OF PHARMACY**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

13 **LIMA'S PROFESSIONAL PHARMACY**  
14 **INC., dba LIMA'S PROFESSIONAL**  
15 **PHARMACY; ROBERT LIMA, CEO and**  
16 **50% Shareholder; and RAMONA LIMA,**  
17 **Secretary and 50% Shareholder**  
2097 Harrison Avenue  
Eureka, CA 95501

18 **Pharmacy Permit No. PHY 43124**

19 **Sterile Compounding License No. LSC**  
**100544**

20 **RAMONA LIMA**  
2097 Harrison Avenue  
Eureka, CA 95501

21 **Pharmacist License No. RPH 46446**

22 Respondents.  
23  
24

Case No. 7269

**ACCUSATION**

25 **PARTIES**

26 1. Anne Sodergren (Complainant) brings this Accusation solely in her official capacity  
27 as the Executive Officer of the Board of Pharmacy (Board), Department of Consumer Affairs.

28 *////*

2. On or about December 16, 1997, the Board issued Pharmacy Permit Number PHY 43124 to Partners, Robert Brede Lima and Ramona Lima, 50% shareholders, to do business as Lima's Professional Pharmacy. On or about September 27, 2007, the Board authorized a tradestyle change to Permit Number PHY 43124, allowing Lima's Professional Pharmacy Inc., to do business as Lima's Professional Pharmacy (Respondent Lima's Pharmacy). The Pharmacy Permit is in full force and effect, and will expire on December 1, 2023, unless renewed.

3. On or about June 21, 2014, the Board issued Sterile Compounding License Number LSC 100544 to Respondent Lima's Pharmacy. The Sterile Compounding License is in full force and effect, and will expire on December 1, 2023, unless renewed.

4. On or about August 17, 1993, the Board issued Pharmacist License Number RPH 46446 to Ramona Lima (Respondent Lima). The Pharmacist License is in full force and effect, and will expire on February 28, 2023, unless renewed. At all times relevant, Respondent Lima is and has been Secretary, 50% owner, and Pharmacist-in-Charge of Respondent Lima's Pharmacy.

5. At all times relevant, Robert Lima is and has been the Chief Executive Officer and 50% owner of Respondent Lima's Pharmacy.

### **JURISDICTION**

6. This Accusation is brought before the Board under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.

7. Section 4300 states, in part:

"(a) Every license issued may be suspended or revoked."

8. Section 4300.1 states, in part:

"The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license."

////

////

7. Section 4307 states, in pertinent part:

“(a) Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was under suspension, or who has been a manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of any partnership, corporation, trust, firm, or association whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control had knowledge of or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation, shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, partner, or in any other position with management or control of a licensee as follows:

“(1) Where a probationary license is issued or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.

“(2) Where the license is denied or revoked, the prohibition shall continue until the license is issued or reinstated.

“(b) ‘Manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of a license’ as used in this section and Section 4308, may refer to a pharmacist or to any other person who serves in such capacity in or for a licensee.  
. . . .”

## INTRODUCTION

8. This disciplinary action relates to Respondents' compounding of prescription drugs, including drugs designated for sterile administration, in a pharmacy. Pharmacy compounding is when a licensed pharmacist combines, mixes, or alters drug ingredients to create a medication tailored to the needs of an individual patient. (Cal. Code Regs., tit. 16, § 1735.) Compounding is a form of drug manufacturing subject to the requirements of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § *et seq.*]. Compounding in a pharmacy as a form of drug manufacturing is permitted under federal law by Section 503A of the FDCA [21 U.S.C. § 353a].

1           9.     The Food and Drug Administration (FDA) oversees drug manufacturing, but does not  
2 license pharmacies or pharmacists, nor control when or how their licenses permit compounding.  
3 The states issue these licenses, and have primary jurisdiction. The states also set compounding  
4 standards that complement FDA standards for compounding as a form of drug manufacturing.

5           10.    California law authorizes the Board to treat violations of federal statutes regulating  
6 controlled substances and dangerous drugs, as well as federal laws and regulations governing  
7 pharmacy practice, as grounds for discipline. (Bus. & Prof. Code, § 4301, subds. (j) and (o).)

8     *Adulterated Drugs and Drugs Lacking Quality*

9           11.    Under federal and California law, any drug, including a compounded preparation,  
10 must not be “adulterated” by containing “any filthy, putrid, or decomposed substance” or by  
11 having been “prepared, packed, or held under insanitary conditions whereby it may have been  
12 contaminated with filth, or whereby it may have been rendered injurious to health.” (21 U.S.C. §  
13 351(1)(1) and (a)(2)(A) [definitions of “adulterated”] and Health & Saf. Code, §§ 11250 and  
14 11255 [same]; see also 21 U.S.C. § 331(a), (b), and (a) [prohibitions regarding adulterated drugs]  
15 and Health & Saf. Code, § 11295 [same].) In addition, all compounding must be consistent with  
16 standards in the pharmacy compounding chapters of the current United States Pharmacopeia-  
17 National Formulary (USP-NF), including relevant testing and quality assurance standards. (Bus.  
18 & Prof. Code, § 4126.8; see Cal. Code Regs., tit. 16, § 1735.1(a)(e) [definition of “quality”].)  
19 The California Pharmacy Law also contains additional standards that supplement the USP-NF  
20 standards. (*Id.*; see, e.g., Bus. & Prof. Code, §§ 4126.10, 4127 *et seq.*, 4128 *et seq.*, 4129 *et seq.*,  
21 Cal. Code Regs., tit. 16, §§ 1735 *et seq.*, 1751 *et seq.*) To ensure appropriate quality, pharmacies  
22 are expected to compound solely from ingredients intended for use in pharmaceutical products.

23     *Sterile Compounding and Specialty Compounding Licenses*

24           12.    Drug compounds may either be “sterile” or “non-sterile,” depending on the intended  
25 route of administration of the drug. Sterile drugs are those intended for administration by means  
26 other than through the digestive system, e.g., injectables, or ophthalmic or inhalation drugs in  
27 aqueous format. Because these drugs bypass some of the body’s natural defenses against  
28 pathogens and impurities, it is important that they are sterile and uncontaminated.

1           13. California law permits all licensed pharmacists to compound non-sterile drug  
2 products in licensed pharmacies. (e.g., Bus. & Prof. Code, §§ 4307, 4051, and 4110.) But  
3 specialty licenses are required for compounding sterile drug products (Bus. & Prof. Code, § 4127  
4 *et seq.*) and drugs derived from human whole blood (Health & Saf. Code, § 1602.5). And to  
5 ensure safety, additional procedures apply to pharmacies compounding such drugs, including  
6 testing for sterility and pyrogens. (Cal. Code Regs., tit. 16, § 1751.7(e)(1).)

7                                   **STATUTORY AND REGULATORY PROVISIONS**

8           14. Section 4022 states:

9           “‘Dangerous drug’ or ‘dangerous device’ means any drug or device unsafe for self-use in  
10 humans or animals, and includes the following:

11           “(a) Any drug that bears the legend: ‘Caution: federal law prohibits dispensing without  
12 prescription,’ ‘Rx only,’ or words of similar import.

13           “(b) Any device that bears the statement: ‘Caution: federal law restricts this device to sale  
14 by or on the order of a \_\_\_\_\_,’ ‘Rx only,’ or words of similar import, the blank to be filled  
15 in with the designation of the practitioner licensed to use or order use of the device.

16           “(c) Any other drug or device that by federal or state law can be lawfully dispensed only on  
17 prescription or furnished pursuant to Section 4006.”

18           15. Section 4036.5 states:

19           “‘Pharmacist-in-charge’ means a pharmacist proposed by a pharmacy and approved by the  
20 board as the supervisor or manager responsible for ensuring the pharmacy’s compliance with all  
21 state and federal laws and regulations pertaining to the practice of pharmacy.”

22           16. Section 4113, subdivision (c) states:

23           “(c) The pharmacist-in-charge shall be responsible for a pharmacy’s compliance with all  
24 state and federal laws and regulations pertaining to the practice of pharmacy.”

25           17. Section 4169, subdivision (a)(2) state, in pertinent part:

26           “(a) A person or entity shall not do any of the following:

27           . . .

28       /////



1 “(2) Purchase, trade, sell, or transfer dangerous drugs that the person knew or reasonably  
2 should have known were adulterated, as set forth in Article 2 (commencing with Section 111250)  
3 of Chapter 6 of Part 5 of Division 104 of the Health and Safety Code.”

4 18. Section 4301 states, in pertinent part:

5 “The board shall take action against any holder of a license who is guilty of unprofessional  
6 conduct or whose license has been issued by mistake. Unprofessional conduct includes, but is not  
7 limited to, any of the following:

8 . . .

9 “(f) The commission of any act involving moral turpitude, dishonesty, fraud, deceit, or  
10 corruption, whether the act is committed in the course of relations as a licensee or otherwise, and  
11 whether the act is a felony or misdemeanor or not.

12 . . .

13 “(j) The violation of any of the statutes of this state, of any other state, or of the United  
14 States regulating controlled substances and dangerous drugs.

15 . . .

16 “(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the  
17 violation of or conspiring to violate any provision or term of this chapter or of the applicable  
18 federal and state laws and regulations governing pharmacy, including regulations established by  
19 the board or by any other state or federal regulatory agency.

20 “(p) Actions or conduct that would have warranted denial of a license.

21 . . . .”

22 19. Section 4306.5, subdivisions (a) and (b), state:

23 “Unprofessional conduct for a pharmacist may include any of the following:

24 “(a) Acts or omissions that involve, in whole or in part, the inappropriate exercise of his or  
25 her education, training, or experience as a pharmacist, whether or not the act or omission arises in  
26 the course of the practice of pharmacy or the ownership, management, administration, or  
27 operation of a pharmacy or other entity licensed by the board.

28 /////

1 “(b) Acts or omissions that involve, in whole or in part, the failure to exercise or implement  
2 his or her best professional judgment or corresponding responsibility with regard to the  
3 dispensing or furnishing of controlled substances, dangerous drugs, or dangerous devices, or with  
4 regard to the provision of services.”

5 20. Health and Safety Code section 1602.5 states:

6 “(a) No person shall engage in the production of human whole blood or human whole blood  
7 derivatives unless the person is licensed under this chapter and the human whole blood or human  
8 whole blood derivative is collected, prepared, labeled, and stored in accordance with both of the  
9 following:

10 “(1) The standards set forth in the 13th Edition of ‘Standards for Blood Banks and  
11 Transfusion Services,’ as published by the American Association of Blood Banks and in effect on  
12 November 15, 1989, or any amendments thereto or later published editions or amendments  
13 thereto. These shall be the standards for all licensed blood banks and blood transfusion services in  
14 the state.

15 “(2) Those provisions of Title 17 of the California Code of Regulations that are continued  
16 in effect by subdivision (c) or that are adopted pursuant to subdivision (b).

17 “(b) The department may, by the adoption of regulations, establish and require compliance  
18 with requirements in addition to, or in lieu of, those in subdivision (a) as the department deems  
19 appropriate to reflect changing technology or to improve the safety of human whole blood or  
20 human whole blood derivatives. Any standards adopted pursuant to this subdivision shall be  
21 adopted after consultation with representatives of the American Association of Blood Banks.

22 “(c) Until the time superseded by any regulation adopted pursuant to this section, all of the  
23 provisions of Group 1 (commencing with Section 950) of Subchapter 1 of Chapter 2 of Part 1 of  
24 Title 17 of the California Code of Regulations shall remain in effect with the exception of the  
25 following:

26 “(1) Subdivisions (i) to (k), inclusive, of Section 997.

27 “(2) Sections 999 and 1001.

28 “(3) Subdivisions (a) to (c), inclusive, of Section 1002.

1 “(4) Paragraphs (2) and (3) of subdivision (e) of Section 1002.

2 “(5) Subdivisions (f) and (g) of Section 1002.

3 “(6) Paragraphs (2) to (6), inclusive, of subdivision (h) of Section 1002.

4 “(7) Subdivisions (i), (k), and (l) of Section 1002.

5 “(8) Subdivisions (a) to (c), inclusive, of Section 1004.

6 “(9) Sections 1010, 1012, 1013, 1014, 1024, and 1024.1.

7 “(10) Subdivisions (a), (b), and (e) of Section 1025.

8 “(11) Paragraphs (1) to (3), inclusive, of subdivision (c) of Section 1025.

9 “(d)(1) Any amendment to the 13th Edition of ‘Standards for Blood Banks and Transfusion  
10 Services,’ any later editions, or any amendments thereto, published by the American Association  
11 of Blood Banks shall become effective in California 90 days after the effective date of this  
12 section, or 90 days after publication by the association, unless the department sends written  
13 notice, within such a 90-day period, to all persons licensed under this chapter to engage in the  
14 production of human whole blood or human whole blood derivatives, indicating which portions  
15 shall not become effective.

16 “(2) The department may determine that no portion of any amendments or later editions  
17 shall become effective. The department shall determine that no portion of an amendment or later  
18 edition shall become effective pursuant to this section whenever the department has not received  
19 a copy of the amendment or later edition by the date it is published by the American Association  
20 of Blood Banks.”

21 21. Health and Safety Code section 111250 states:

22 “Any drug or device is adulterated if it consists, in whole or in part, of any filthy, putrid, or  
23 decomposed substance.”

24 22. Health and Safety Code section 111255 states:

25 “Any drug or device is adulterated if it has been produced, prepared, packed, or held under  
26 conditions whereby it may have been contaminated with filth, or whereby it may have been  
27 rendered injurious to health.”

28 /////

1           23. Health and Safety Code section 111295 states:

2           “It is unlawful for any person to manufacture, sell, deliver, hold, or offer for sale any drug  
3 or device that is adulterated.”

4           24. California Code of Regulations, title 16, section 1735.1, subdivision (ae) states:

5           “(ae) ‘Quality’ means the absence of harmful levels of contaminants, including filth, putrid,  
6 or decomposed substances, the absence of active ingredients other than those listed on the label,  
7 and the absence of inactive ingredients other than those listed on the master formula document.”

8           25. California Code of Regulations, title 16, section 1735.2 states, in pertinent part:

9           ...

10           “(g) The pharmacist performing or supervising compounding is responsible for the  
11 integrity, potency, quality, and labeled strength of a compounded drug preparation until the  
12 beyond use date indicated on the label, so long as label instructions for storage and handling are  
13 followed after the preparation is dispensed.

14           ...

15           “(i) Every compounded drug preparation shall be given a beyond use date representing the  
16 date or date and time beyond which the compounded drug preparation should not be used, stored,  
17 transported or administered, and determined based on the professional judgment of the pharmacist  
18 performing or supervising the compounding.

19           ...

20           “(3) For sterile compounded drug preparations, extension of a beyond use date is only  
21 allowable when supported by the following:

22           “(A) Method Suitability Test,

23           “(B) Container Closure Integrity Test, and

24           “(C) Stability Studies

25           ...”

26           26. California Code of Regulations, title 16, section 1735.3, subdivision (a)(2)(F), states:

27           “(a) For each compounded drug preparation, pharmacy records shall include:

28           ...

1 “(2) A compounding log consisting of a single document containing all of the following:

2 . . .

3 “(F) The manufacturer, expiration date and lot number of each component. If the  
4 manufacturer name is demonstrably unavailable, the name of the supplier may be substituted. If  
5 the manufacturer does not supply an expiration date for any component, the records shall include  
6 the date of receipt of the component in the pharmacy, and the limitations of section 1735.2,  
7 subdivision (l) shall apply.

8 “(i) Exempt from the requirements in this paragraph (1735.3(a)(2)(F)) are sterile  
9 preparations compounded in a single lot for administration within seventy-two (72) hours to a  
10 patient in a health care facility licensed under section 1250 of the Health and Safety Code and  
11 stored in accordance with standards for ‘Redispensed CSPs’ found in Chapter 797 of the United  
12 States Pharmacopeia - National Formulary (USP37-NF32) Through 2nd Supplement (37th  
13 Revision, Effective December 1, 2014), hereby incorporated by reference.”

14 27. California Code of Regulations, title 16, section 1751.7, subdivision (e)(1), states:

15 “(e)(1) Batch-produced sterile drug preparations compounded from one or more non-sterile  
16 ingredients, except as provided in paragraph (2), shall be subject to documented end product  
17 testing for sterility and pyrogens and shall be quarantined until the end product testing confirms  
18 sterility and acceptable levels of pyrogens. Sterility testing shall be USP chapter 71 compliant and  
19 pyrogens testing shall confirm acceptable levels of pyrogens per USP chapter 85 limits, before  
20 dispensing. This requirement of end product testing confirming sterility and acceptable levels of  
21 pyrogens prior to dispensing shall apply regardless of any sterility or pyrogen testing that may  
22 have been conducted on any ingredient or combination of ingredients that were previously non-  
23 sterile. Exempt from pyrogen testing are topical ophthalmic and inhalation preparations.”

24 28. California Code of Regulations, title 16, section 1774, subdivision (a)(1), states:

25 “(a) Unless otherwise directed by the Board, any pharmacy permit which is on probation to  
26 the Board shall be subject to the following conditions:

27 “(1) Obey all laws and regulations substantially related to the practice of pharmacy;”

28 . . . .”

1 **COST RECOVERY**

2 29. Section 125.3 provides, in part, that the Board may request the administrative law  
3 judge to direct a licentiate found to have committed a violation or violations of the licensing act to  
4 pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

5 **RELEVANT DRUGS**

6 30. Avastin, also known as bevacizumab, is a dangerous drug as designated by Business  
7 and Professions Code section 4022.

8 31. Methylcobalamin (methyl vitamin B12) is the synthetic and active form of cobalamin  
9 (vitamin B12) that helps in synthesis of methionine and S-adenosylmethionine. Methylcobalamin  
10 is required for integrity of myelin, neuronal function, proper red blood cell formation and DNA  
11 synthesis. Cobalamin is an essential nutrient which is not synthesized in humans and therefore  
12 must be obtained by dietary intake or supplementation. Cobalamin is created by bacteria and can  
13 only be found naturally in animal products; however, synthetic forms are widely available as  
14 dietary supplements and added to many foods such as packaged cereals.

15 Cobalamin can be converted by the liver to methylcobalamin, unless an individual has  
16 methenyltetrahydrofolate synthetase deficiency disorder. Methenyltetrahydrofolate synthetase  
17 deficiency is a rare neurodevelopmental disorder caused by mutations affecting the MTHFS gene  
18 and is generally diagnosed at birth or early infancy.

19 Cyanocobalamin is the only FDA approved commercially available injectable drug product  
20 indicated to treat deficiencies in inadequate absorption such as pernicious anemia.

21 Injectable Methylcobalamin is not an FDA approved product to treat any disease or  
22 disorder.

23 There are many nonprescription oral dietary supplements with either cyanocobalamin or  
24 methylcobalamin meant to alleviate insufficient dietary intake.

25 Methylcobalamin infusions are not FDA approved for any indication, and are dangerous  
26 drugs as defined by Business and Professions Code section 4022.

27 32. Tri-Mix, also known as Papaverine/Phentolamine/Prostaglandin (Pap/Phent/PGE1), is  
28 a dangerous drug as designated by Business and Professions Code section 4022.

1 **FIRST CAUSE FOR DISCIPLINE**

2 (Failure to Maintain the Quality of Compounded Sterile Preparations)

3 33. Respondents subjected their Pharmacy Permit, Sterile Compounding License, and  
4 Pharmacist License to discipline in that, between January 25, 2019 and June 7, 2021,  
5 Respondents compounded and sold at least 143 vials of Methylcobalamin 1mg/ml injection that  
6 lacked quality because they were compounded from an ingredient not graded for pharmaceutical  
7 use. (Bus. & Prof. Code, §§ 4113, subd. (c); 4301, subd. (o), 4306.5, subds. (a) and (b); Cal.  
8 Code Regs., tit. 16, §§ 1735.1, subd. (ae), 1735.2, subd. (g).)

9 **SECOND CAUSE FOR DISCIPLINE**

10 (Adulterated Preparations)

11 34. Respondents subjected their Pharmacy Permit, Sterile Compounding License, and  
12 Pharmacist License to discipline in that, between January 25, 2019 and June 7, 2021,  
13 Respondents compounded and sold at least 143 vials of Methylcobalamin 1mg/ml injection that  
14 were adulterated in that they were compounded from an active pharmaceutical ingredient not  
15 graded for pharmaceutical use. (Bus. & Prof. Code, §§ 4113, subd. (c), 4169, subd. (a)(2), 4301,  
16 subds. (j) and (o); Health & Saf. Code, §§ 111250, 111255, 111295.)

17 **THIRD CAUSE FOR DISCIPLINE**

18 (Failure to Conduct Pyrogen and USP 71 Complaint Sterility Testing)

19 35. Respondents subjected their Pharmacy Permit, Sterile Compounding License, and  
20 Pharmacist License to discipline in that, between January 25, 2019 and June 7, 2021,  
21 Respondents compounded and sold several batch-produced injectable Methylcobalamin and  
22 Papaverine/Phentolamine/PGE1 drug preparations, compounded from one or more non-sterile  
23 ingredients, without conducting and documenting end product sterility and pyrogen testing. (Bus.  
24 & Prof. Code, §§ 4113, subd. (c), 4301, subd. (o); Cal. Code Regs., tit. 16, § 1751.7, subd. (e)(1).)

25 **FOURTH CAUSE FOR DISCIPLINE**

26 (Failure to Support Extended Beyond Use Dates)

27 36. Respondents subjected their Pharmacy Permit, Sterile Compounding License, and  
28 Pharmacist License to discipline for compounding and selling drug preparations with contents

beyond their use date without providing support, in the form of tests or studies, for extension of beyond use dates. (Bus. & Prof. Code, §§ 4113, subd. (c), 4301, subd. (o); Cal. Code Regs., tit. 16, § 1735.2, subd. (i)(3)(A), (B), (C).) In particular, between January 25, 2019 and June 7, 2021, Respondents compounded and sold several batch-produced injectable Methylcobalamin and Papaverine/Phentolamine/PGE1 drug preparations compounded from one or more non-sterile ingredients, that were beyond their use date, without support for the extension of their beyond use date. And between January 25, 2019 and June 7, 2021, Respondents compounded and sold about 4,448 units of bevacizumab (Avastin) beyond their use date without support for any extension.

#### **FIFTH CAUSE FOR DISCIPLINE**

(Failure to Maintain Complete Compounding Logs)

37. Respondents subjected their Pharmacy Permit, Sterile Compounding License, and Pharmacist License to discipline in that, between January 25, 2019 and June 7, 2021, for several batch-produced injectable Methylcobalamin and Papaverine/Phentolamine/PGEI preparations compounded from one or more non-sterile ingredients, Respondents failed to list manufacturers of each component in several compounding logs. (Bus. & Prof. Code, §§ 4113, subd. (c), 4301, subd. (o); Cal. Code Regs., tit. 16, § 1735.3, subd. (a)(2)(F).)

#### **SIXTH CAUSE FOR DISCIPLINE**

(Production of Human Whole Blood Derivatives Without a License)

38. Respondents subjected their Pharmacy Permit, Sterile Compounding License, and Pharmacist License to discipline in that, between January 25, 2019 and June 7, 2021, Respondents prepared and dispensed 786 syringes of blood-derived autologous serum eye drops, without a license permitting them to produce human-blood-derived products. (Bus. & Prof. Code, §§ 4113, subd. (c), 4301, subds. (j), (o); Health and Saf. Code, § 1602.5.)

////

////

////

////

////



**DISCIPLINARY CONSIDERATIONS**

39. To determine the degree of discipline, if any, to be imposed on Respondents' Pharmacy Permit, Sterile Compounding License, and Pharmacist License, Complainant further alleges the following:

a. Effective January 25, 2019, in a Decision and Order issued by the Board of Pharmacy in settlement of a disciplinary action against Respondents titled *In the Matter of the Accusation Against Lima's Professional Pharmacy et al.*, Respondents' Pharmacy Permit, Sterile Compounding License, and Pharmacist License were each revoked, with each revocation stayed subject to Respondents' successful completion of two years of probation, on specific terms and conditions. Respondents' terms of probation were completed on January 25, 2021.

b. The operative pleading in that case, an Accusation, alleged the following six causes for discipline:

i. Failure to Disinfect Surfaces in the Compounding Area (Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, § 1751.4, subd. (d));

ii. Failure to Wear Required Personal Protective Equipment (Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, § 1751.5, subd. (b)(1));

iii. Failure to Ensure that Compounding Staff Has Necessary Knowledge and Skills (Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, § 1751.6, subd. (e)(1)(F));

iv. Failure to Quarantine Batch-Produced Sterile Drug Preparations (Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, § 1751.7, subd. (c));

v. Failure to Maintain Facilities, Fixtures, and Equipment (Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, § 1714, subd. (b)); and

vi. Failure to Maintain Training Documentation (Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, §§ 1735.7, subds. (a) and (b), 1751.6, subds. (b), (c), (e)(1), (e)(2), 1751.7, subd. (b).)

In resolving this matter, Respondents admitted the truth of each of cause for discipline.

c. In settlement of the disciplinary action, Respondents agreed, *inter alia*, to Probation Condition Number 2 which provided that Respondents "shall obey all state and federal

1 laws and regulations.” Respondents also admitted a prior administrative history. In particular, on  
2 or about May 8, 2018, the Board of Pharmacy issued to Respondent Lima’s Pharmacy, with  
3 regard to Pharmacy Permit Number PHY 43124, Citation No. CI 2016 75395, alleging unlawful  
4 Variation from Prescription (Cal. Code Regs., tit. 16, § 1716). The Citation is complete and final.

5 **OTHER MATTERS**

6 40. Pursuant to Section 4307, if discipline is imposed on Pharmacy Permit Number PHY  
7 43124 or Sterile Compounding License Number LSC 100544, Lima’s Professional Pharmacy  
8 Inc., doing business as Lima’s Professional Pharmacy, shall be prohibited from serving as  
9 manager, administrator, owner, member, officer, director, associate, or partner of a licensee for  
10 five years if Pharmacy Permit Number PHY 43124 or Sterile Compounding License Number  
11 LSC 100544 is placed on probation or until Pharmacy Permit Number PHY 43124 or Sterile  
12 Compounding License Number LSC 100544 is reinstated if either is revoked.

13 41. Pursuant to Section 4307, if discipline is imposed on Pharmacy Permit Number PHY  
14 43124 or Sterile Compounding License Number LSC 100544, while Ramona Lima was an officer  
15 and/or owner and had knowledge of or knowingly participated in any conduct for which the  
16 license was disciplined, Ramona Lima shall be prohibited from serving as a manager,  
17 administrator, owner, member officer, director, associate, or partner of a licensee for five years if  
18 Pharmacy Permit Number PHY 43124 or Sterile Compounding License Number LSC 100544 is  
19 placed on probation or until Pharmacy Permit Number PHY 43124 or Sterile Compounding  
20 License Number LSC 100544 is reinstated if either is revoked.

21 42. Pursuant to Section 4307, if discipline is imposed on Pharmacy Permit Number PHY  
22 43124 or Sterile Compounding License Number LSC 100544, while Robert Lima was an officer  
23 and/or owner and had knowledge of or knowingly participated in any conduct for which the  
24 license was disciplined, Robert Lima shall be prohibited from serving as a manager,  
25 administrator, owner, member officer, director, associate, or partner of a licensee for five years if  
26 Pharmacy Permit Number PHY 43124 or Sterile Compounding License Number LSC 100544 is  
27 placed on probation or until Pharmacy Permit Number PHY 43124 or Sterile Compounding  
28 License Number LSC 100544 is reinstated if either is revoked.

43. Pursuant to Section 4307, if discipline is imposed on Pharmacist License Number RPH 46446, Ramona Lima shall be prohibited from serving as a manager, administrator, owner, member officer, director, associate, or partner of a licensee for five years if Pharmacist License Number RPH 46446 is placed on probation or until Pharmacist License Number RPH 46446 is reinstated if it is revoked.

**PRAYER**

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

1. Revoking or suspending Pharmacy Permit Number PHY 43124, issued to Respondent Lima's Professional Pharmacy Inc., doing business as Lima's Professional Pharmacy;

2. Revoking or suspending Sterile Compounding Pharmacy License Number LSC 100544, issued to Respondent Lima's Professional Pharmacy Inc., doing business as Lima's Professional Pharmacy;

3. Revoking or suspending Pharmacist License Number RPH 46446, issued to Respondent Ramona Lima;

4. Prohibiting Ramona Lima from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Sterile Compounding Pharmacy License Number LSC 100544 or Pharmacy Permit Number PHY 43124 is placed on probation or until Sterile Compounding Pharmacy License Number LSC 100544 or Pharmacy Permit Number PHY 43124 is reinstated if either is revoked;

5. Prohibiting Robert Lima from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Sterile Compounding Pharmacy License Number LSC 100544 or Pharmacy Permit Number PHY 43124 is placed on probation or until Sterile Compounding Pharmacy License Number LSC 100544 or Pharmacy Permit Number PHY 43124 is reinstated if either is revoked;

6. Prohibiting Ramona Lima from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacist License Number

////

1 RPH 46446 is placed on probation or until Pharmacist License Number RPH 46446 is reinstated  
2 if it is revoked;

3 7. Ordering Respondent Lima's Professional Pharmacy Inc., doing business as Lima's  
4 Professional Pharmacy, and Respondent Ramona Lima to pay the Board of Pharmacy the  
5 reasonable costs of the investigation and enforcement of this case, pursuant to Business and  
6 Professions Code section 125.3; and

7 8. Taking such other and further action as deemed necessary and proper.

9 DATED: 3/10/2023

Sodergren,  
Anne@DCA

Digitally signed by  
Sodergren, Anne@DCA  
Date: 2023.03.10 07:30:33  
-08'00'

ANNE SODERGREN  
Executive Officer  
Board of Pharmacy  
Department of Consumer Affairs  
State of California  
*Complainant*

14 SF2022400514 / 43235123.docx